Tyvaso DPI: Drug-device characteristics, patient clinical...
Dec 13, 2023 15:18:35 GMT -5
nxc2, peppy, and 3 more like this
Post by RainbowUnicorn on Dec 13, 2023 15:18:35 GMT -5
www.sciencedirect.com/science/article/pii/S1094553923000780?via%3Dihub
6. Summary
DPIs have been in use for decades as a safe, efficient, and simple way to deliver medications to the lungs while minimizing systemic AEs. The technology has been approved for multiple diseases, including asthma, COPD, diabetes, and recently PAH and PH-ILD [21,32,40]. However, DPI devices vary in important parameters that may change suitability for some patient types.
While many have incorrect beliefs about high-resistance devices, research and real-world clinical evidence have shown that patients with pulmonary disease, including PH, can generate the inspiratory force needed to properly use these devices [21,51,54]. Additionally, low-flow, high-resistance devices improve lung deposition by reducing oropharynx impaction rates [55]. Inspiratory pressure generated by a patient's inspiratory effort is important for controlling DPI device efficacy [55].
Clinical studies of Tyvaso DPI have found that it led to improvements in 6MWD and increased patient satisfaction after switching from nebulized treprostinil [21]. Patients enrolled in BREEZE also experienced mild AEs, and tolerability seemingly improves with time [11,21].
Tyvaso DPI may be considered as a first prostacyclin agent or for those that do not tolerate other prostacyclin agents, patients with pulmonary comorbidities, patients with mixed Group 1 and Group 3 PH, or those that prefer an active lifestyle and need a portable, non-invasive treatment. The dry powder formulation of treprostinil offers a new option that has been approved for use in patients with PAH and PH-ILD.
6. Summary
DPIs have been in use for decades as a safe, efficient, and simple way to deliver medications to the lungs while minimizing systemic AEs. The technology has been approved for multiple diseases, including asthma, COPD, diabetes, and recently PAH and PH-ILD [21,32,40]. However, DPI devices vary in important parameters that may change suitability for some patient types.
While many have incorrect beliefs about high-resistance devices, research and real-world clinical evidence have shown that patients with pulmonary disease, including PH, can generate the inspiratory force needed to properly use these devices [21,51,54]. Additionally, low-flow, high-resistance devices improve lung deposition by reducing oropharynx impaction rates [55]. Inspiratory pressure generated by a patient's inspiratory effort is important for controlling DPI device efficacy [55].
Clinical studies of Tyvaso DPI have found that it led to improvements in 6MWD and increased patient satisfaction after switching from nebulized treprostinil [21]. Patients enrolled in BREEZE also experienced mild AEs, and tolerability seemingly improves with time [11,21].
Tyvaso DPI may be considered as a first prostacyclin agent or for those that do not tolerate other prostacyclin agents, patients with pulmonary comorbidities, patients with mixed Group 1 and Group 3 PH, or those that prefer an active lifestyle and need a portable, non-invasive treatment. The dry powder formulation of treprostinil offers a new option that has been approved for use in patients with PAH and PH-ILD.